Retatrutide 30 mg

Description

Retatrutide (LY3437943) is studied in GLP-1, GIP and glucagon receptor signalling. This 30 mg catalogue format is separate from our 10 mg listing.

Retatrutide 30 mg: research context

Compare the compound, formulation and stated quantity with the requirements of the experimental model. Literature about retatrutide does not certify the identity or quality of an individual vial.

Product format and batch documentation

The stated quantity describes the catalogue format, not a dosing instruction. Confirm compound identity, formulation, batch reference and documented content against the original supplier records. Follow verified product-specific handling instructions and your laboratory’s approved methods.

Use the searchable CoA Library to review available original supplier reports. A report for another strength or batch does not certify this listing. Our analytical testing guide explains identity, purity and the limits of different methods.

Availability and related formats

In stock. Contact Edinburgh Peptide for product documentation before selecting materials.

Compare Retatrutide 10 mg, browse the research catalogue, or contact Edinburgh Peptide for product documentation.

UK delivery and research use

Read our UK delivery information for current delivery terms. For in-vitro laboratory research only; not for human or veterinary use. See the research-use disclaimer.